Long-Term Oncologic Outcomes in Patients With Muscle Invasive Bladder Cancer Misclassified as Achieving a Complete Clinical Response to Neoadjuvant Chemotherapy
Open Access
- 1 September 2024
- journal article
- research article
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Abstract
Introduction: Correctly classifying patients with muscle invasive bladder cancer (MIBC) as achieving a complete clinical response (CCR) to neoadjuvant chemotherapy (NAC) is challenging without radical cystectomy (RC) pathology. The accuracy of clinical staging following NAC is debated, and the risk of occult residual MIBC is real. We present the rate and oncologic outcomes of patients who were misclassified as achieving a CCR to NAC. Materials and Methods: We utilized our prospective database of patients who achieved a CCR to NAC and elected active surveillance (AS). Patients with intravesical MIBC within 6 months of CCR classification were defined as potentially misclassified (mCCR). We used Kaplan-Meier curves to assess overall (OS), cancer-specific (CSS), and metastasis-free (MFS) survival and log-rank tests to evaluate differences between cohorts. Results: Fifty-four patients, median age of 70 years and follow-up of 49 months, were included. Six patients (11%) were mCCR, and all underwent delayed RC at a mean of 4.3 months after CCR classification. Pre-NAC hydronephrosis was more common in mCCR patients (67% vs 8%, P < .01). Five-year OS, CSS, and MFS for mCCR patients were 63% each, compared with 80%, 89%, and 93%, for the remaining patients. Log-rank tests demonstrated significantly lower OS (P = .03) and MFS (P = .05) in mCCR patients. Conclusions: We observed an 11% CCR misclassification rate. While mCCR patients had significantly worse OS and MFS compared with correctly classified CCR patients, we cannot know for certain how survival outcomes would have changed with immediate RC. Our findings are useful when describing the risks of misclassification to CCR patients contemplating AS.Keywords
This publication has 9 references indexed in Scilit:
- Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trialNature Medicine, 2024
- Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective TrialJournal of Urology, 2021
- Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerEuropean Urology, 2021
- Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort StudyJournal of Urology, 2018
- Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical CystectomyUrology, 2018
- Pathological T0 Following Radical Cystectomy with or without Neoadjuvant Chemotherapy: A Useful SurrogateJournal of Urology, 2014
- Preoperative Hydronephrosis Predicts Extravesical and Node Positive Disease in Patients Undergoing Cystectomy for Bladder CancerJournal of Urology, 2010
- Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only SeriesEuropean Urology, 2007
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003